Intravenous Oxytocin for Recovery After Total Hip Replacement

DR
RC
Overseen ByRegina Curry, R.N.
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Wake Forest University Health Sciences
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to test whether perioperative intravenous (IV) oxytocin compared to placebo results in faster recovery in disability as measured by daily steps over 56 days after Total Hip Arthroplasty (THA).

Who Is on the Research Team?

DR

Douglas Ririe, M.D.

Principal Investigator

Wake Forest University School of Meidcine

Are You a Good Fit for This Trial?

Inclusion Criteria

I am between 18 and 75 years old.
I am scheduled for my first total hip replacement on one hip.
* Able to read and write English and have a stable residence.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intravenous oxytocin or placebo to assess recovery speed after Total Hip Arthroplasty

8 weeks
Regular monitoring visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

8 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Intravenous Oxytocin

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: OxytocinExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Wake Forest University Health Sciences

Lead Sponsor

Trials
1,432
Recruited
2,506,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+